Overall, our study identified a novel and reliable M2-like TAM-associated molecular subtype and constructed a prognostic model, which can be used to predict OS and immunotherapeutic response in BC, and also explored the potential role of DLG3 in the immunosuppressive microenvironment of BC. This evidence concerns the gene DLG3 and breast cancer.